Skip to search formSkip to main contentSkip to account menu

lymphokine-activated killer cell therapy

Known as: LAK cell therapy, cell therapy, lymphokine-activated killer, therapy, lymphokine-activated killer cell 
The use of lymphokine-activated killer cells in the treatment of any disease or disorder.
National Institutes of Health

Related topics

Related topics

2 relations
Lymphokine-Activated Killer Cellsinterleukin-2/lymphokine-activated killer cells

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Canine CD8 T cells showing NK cytotoxic activity express mRNAs for NK cell-associated surface molecules.
2004
2004
Interleukin-1-like activities in synovial fluids of patients with rheumatoid arthritis and traumatic synovitis
SummaryInterleukin-1 (Il-1)-like activity in biological fluids was measured by their ability to rectify the Il-1-dependent… 
1999
1999
Neuroleukin mediated differentiation induction of myelogenous leukemia cells.
1997
1997
Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.
1992
1992
Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
Pretreatment of acute myeloblastic leukemia cells with the hemopoietic growth factor interleukin 3 (IL3) increased their… 
1990
1990
Involvement of granzyme B and perforin gene expression in the lytic potential of human natural killer cells.
Natural killer (NK) cells (CD3-) or large granular lymphocytes (LGL) spontaneously kill K562 targets but are unable to kill Daudi… 
Highly Cited
1989
Highly Cited
1989
Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16…
The phenotype and function of lymphocytes from cancer patients treated with repetitive weekly cycles of continuous i.v. infusions… 
1989
1989
Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced…
In this study 15 consecutive melanoma patients were treated with two courses of bolus recombinant interleukin 2 (rIL2) and rIL2… 
1989
1989
Enhancement of Therapeutic Effect of Interleukin‐2 on Spontaneous Pulmonary Metastases of Lewis Lung Carcinoma by Killer Helper Factor Associated with Increased Induction of Killer Activity
Killer helper factor (KHF) was previously found to be produced by a human T cell hybridoma, 24A CA2. We studied the therapeutic… 
1979
1979
Prostaglandin effect on lymphokine production in multiple sclerosis
Production of the lymphokine LIF (leukocyte migration inhibitory factor) by normal lymphocytes on stimulation with mitogens is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)